Daily Respiratory Research Analysis
Three studies advanced respiratory science and care today: a multicenter prospective study showed shape-sensing robotic bronchoscopy with cone-beam CT enables highly accurate, safe biopsy of small and hard-to-reach pulmonary nodules; a longitudinal lung-microbiome study in ventilated severe community-acquired pneumonia identified a two-taxon signature predicting glucocorticoid response; and a cohort study in cystic fibrosis hemoptysis found n‑butyl‑2‑cyanoacrylate embolization markedly reduced r
Summary
Three studies advanced respiratory science and care today: a multicenter prospective study showed shape-sensing robotic bronchoscopy with cone-beam CT enables highly accurate, safe biopsy of small and hard-to-reach pulmonary nodules; a longitudinal lung-microbiome study in ventilated severe community-acquired pneumonia identified a two-taxon signature predicting glucocorticoid response; and a cohort study in cystic fibrosis hemoptysis found n‑butyl‑2‑cyanoacrylate embolization markedly reduced recurrence versus tris‑acryl microspheres.
Research Themes
- Image-guided robotic diagnostics for peripheral pulmonary nodules
- Microbiome-informed precision corticosteroid stewardship in severe pneumonia
- Interventional radiology optimization for cystic fibrosis hemoptysis
Selected Articles
1. Lung microbiome signatures and explainable predictive modeling of glucocorticoid response in severe community acquired pneumonia.
In 200 ventilated SCAP patients treated with hydrocortisone, longitudinal lung microbiome shifts diverged between survivors and non-survivors by day 7. A parsimonious random‑forest model using only Bacilli and Alphaproteobacteria predicted steroid treatment success with AUROC 0.89, outperforming APACHE II, SOFA, and mNUTRIC. Results suggest SG imposes ecological pressure and that microbiome-aware models can enable precision corticosteroid stewardship.
Impact: Introduces an explainable, minimal microbiome fingerprint that robustly predicts glucocorticoid response in severe pneumonia, potentially reducing futile steroid exposure.
Clinical Implications: Supports integrating lower-airway microbiome profiling to stratify steroid use in SCAP, guiding precision immunomodulation instead of relying solely on severity scores.
Key Findings
- Day-7 lung microbiome diverged: survivors enriched Actinobacteria/Gammaproteobacteria; non-survivors enriched Alphaproteobacteria/Campylobacteria.
- A 2-feature random-forest model (Bacilli, Alphaproteobacteria) achieved AUROC 0.89 (Se 0.83, Sp 0.81), outperforming APACHE II, SOFA, mNUTRIC.
- Findings indicate systemic glucocorticoids reshape the lower-airway microbiome under ICU conditions.
Methodological Strengths
- Prospective longitudinal sampling on ICU days 1, 3, and 7 with both 16S and metagenomics.
- Reproducible bioinformatics workflow and patient-held-out test evaluation with clear performance metrics.
Limitations
- Observational design without interventional allocation; residual confounding cannot be excluded.
- External clinical validation and impact on outcomes from microbiome-guided decision-making remain untested.
Future Directions: Prospective trials to test microbiome-guided corticosteroid stewardship in SCAP and to evaluate causality between steroid exposure and ecological shifts.
INTRODUCTION: Systemic glucocorticoids (SG) are administered to quell hyper-inflammation in severe community acquired pneumonia (SCAP), yet trials report inconsistent efficacy and no mechanistic explanation. METHODS: We enrolled 200 ventilated SCAP patients, whom received hydrocortisone within 48 h of ICU admission, and generated longitudinal lower-airway microbiome profiles by 16S rRNA amplicon and metagenomic sequencing on ICU Days 1, 3 and 7. Compositional data were integrated with clinical variables through a fully reproducible bioinformatics analysis workflow. RESULTS: Baseline community structures did not differ between SG and control cohorts, but by Day 7 survivors exhibited enrichment of Actinobacteria and Gammaproteobacteria whereas non-survivors accumulated Alphaproteobacteria and Campylobacteria. A random-forest model restricted to Bacilli and Alphaproteobacteria achieved AUROC = 0.89 (sensitivity 0.83, specificity 0.81) on a patient-held-out test set, significantly outperforming conventional severity indices like APACHE II, SOFA and mNUTRIC scores. DISCUSSION: Collectively, our results demonstrate that SG therapy imposes reproducible ecological pressures on the lung microbiome and that a two-feature microbial fingerprint can forecast treatment success with single-sample resolution. These findings show that SG therapy actively reshapes the respiratory ecosystem and that lightweight microbiome-aware machine learning can stratify treatment response, offering a tractable path toward precision corticosteroid stewardship.
2. Tool in lesion verification of shape-sensing robotic-assisted bronchoscopy with cone beam CT in sampling peripheral pulmonary nodules.
In a multicenter prospective cohort of 200 patients, shape-sensing robotic bronchoscopy with CBCT achieved 99% tool-in-lesion confirmation, 92% diagnostic accuracy, and 95.5% sensitivity for malignancy with only 2% serious adverse events. Performance remained high for nodules <20 mm and those near pleura, fissures, or mediastinum, indicating robust utility across challenging anatomies.
Impact: Demonstrates near-universal lesion access and high diagnostic accuracy with low complication rates, supporting broader adoption of CBCT-verified robotic navigation for peripheral nodules.
Clinical Implications: Can increase diagnostic yield and safety for small or anatomically challenging nodules, potentially reducing repeat procedures and expediting treatment decisions.
Key Findings
- Tool-in-lesion confirmation by CBCT in 99.0% (198/200) with strict diagnostic yield 85% and overall diagnostic accuracy 92.0%.
- High performance in difficult settings: nodules <20 mm accuracy 88.2%, within 5 mm of critical structures 100%, peripleural 93.3%.
- Low serious adverse event rate (2%), pneumothorax 0.5%.
Methodological Strengths
- Multicenter prospective design with predefined CBCT verification endpoint.
- Comprehensive performance assessment across size and anatomic proximity strata.
Limitations
- Single-arm design without comparator limits direct benchmarking against other navigation modalities.
- Long-term clinical outcomes beyond diagnostic accuracy were not reported.
Future Directions: Head-to-head randomized comparisons with conventional/navigation bronchoscopy and cost-effectiveness analyses; studies linking diagnostic performance to downstream patient outcomes.
INTRODUCTION: Our aim was to evaluate the diagnostic and safety performance of shape-sensing robotic-assisted bronchoscopy (ssRAB) with cone beam CT (CBCT) for the biopsy of pulmonary nodules. Additional analysis was performed to assess outcomes for small nodules and those close to the fissure, pleura or mediastinum. METHODS: This single arm, multicentre prospective study enrolled 200 subjects with suspicious pulmonary nodules. Each subject underwent a ssRAB procedure with CBCT and was subsequently followed up. The primary outcome was tool-in-lesion (TIL) confirmed with CBCT. Further endpoints included diagnostic outcomes and rate of adverse events. RESULTS: Of 200 subjects recruited, 198 subjects had a successful biopsy (whereby lesion was reached and sample was taken) and 97% completed the required follow-up. The median size of the nodules was 13 mm; 26.8% (60/224) have a positive bronchus sign and 181 (80.8%) were located in the outer two-thirds of the lung. TIL was obtained in 99.0% (198/200). The strict diagnostic yield was 85% (170/200) with diagnostic accuracy of 92.0% (184/200) and sensitivity for malignancy of 95.5% (147/154). Diagnostic accuracy for nodules under 20 mm size, within 5 mm from a critical structure (eg, heart, aorta or main pulmonary artery) or from the pleura was 88.2% (172/195), 100% (11/11) and 93.3% (56/60), respectively. There were four (2%) serious procedure-related adverse events, with one patient (0.5%) suffering a pneumothorax. CONCLUSION: ssRAB with CBCT can effectively reach and biopsy small pulmonary nodules, including perifissural, peripleural and paramediastinal lesions with a strong safety profile. TRIAL REGISTRATION NUMBER: NCT05867953.
3. Comparison of n-butyl-2cyanoacrylate and tris-acryl microspheres for bronchial artery embolisation in patients with cystic fibrosis and hemoptysis: a retrospective cohort study.
In 58 cystic fibrosis patients with severe hemoptysis, BAE achieved 98.3% primary clinical success. Over a mean 42.9-month follow-up, recurrence was 50% with tris‑acryl microspheres but 0% with NBCA. Most relapses arose from non-bronchial systemic arteries previously embolized with microspheres; no major adverse events occurred.
Impact: Suggests NBCA may be preferable for durable hemostasis in CF-related hemoptysis, potentially reducing rebleeding and reinterventions.
Clinical Implications: For CF hemoptysis requiring BAE, selecting NBCA could lower recurrence risk, especially when non-bronchial systemic feeders are involved; careful vascular mapping remains essential.
Key Findings
- Primary clinical success of BAE was 98.3% (57/58) with technical success in all cases.
- Hemoptysis recurrence: 50% with tris-acryl microspheres (10/20) vs 0% with NBCA (0/38) over mean 42.9 months (p=0.0005).
- Most recurrences originated from non-bronchial systemic arteries; no major adverse events observed.
Methodological Strengths
- Extended follow-up (~43 months) with clear, clinically relevant endpoints.
- Comparative analysis by embolic agent with assessment of vascular territory involvement.
Limitations
- Retrospective, non-randomized allocation introduces selection bias and confounding.
- Single-center sample size limits generalizability; mechanisms of NBCA durability need elucidation.
Future Directions: Prospective randomized trials comparing embolic agents in CF hemoptysis and mechanistic studies on non-bronchial systemic artery relapse pathways.
AIM: To compare the effectiveness and safety of bronchial artery embolization (BAE) using n-butyl-2-cyanoacrylate (NBCA) versus tris-acryl microspheres in patients with cystic fibrosis. MATERIALS AND METHODS: Fifty-eight patients with severe hemoptysis (>100 mL/24 h) who underwent endovascular embolization between June 2019 and July 2024 were retrospectively analyzed. Patients were divided into two subgroups based on the embolic agent used: NBCA (n = 38) and tris-acryl microspheres (n = 20). Technical success, primary and secondary clinical success, safety, and recurrence rates were evaluated. Potential predictors of recurrence-including the number of pathological arteries identified on CTA, the number and caliber of treated vessels, laterality, and embolized vascular district (bronchial vs. non-bronchial systemic arteries)-were assessed using appropriate univariate tests. RESULTS: Technical success was achieved in all procedures. Primary clinical success was obtained in 57/58 patients (98.3%). During follow-up (mean 42.9 ± 12.3 months), recurrence occurred in 10/58 patients (17.2%), with a significantly higher relapse rate in the microsphere group (10/20, 50%) and no recurrences in the NBCA group (0/38) (p = 0.0005). Most recurrences (7/10) originated from non-bronchial systemic arteries previously embolized with microspheres. No major adverse events were observed. No other variable-including age, number of pathological arteries on CTA, vessel caliber, or laterality-showed a significant association with recurrence. CONCLUSION: NBCA was associated with lower recurrence rates compared with tris-acryl microspheres. More relapses arose from non-bronchial systemic arteries. Further studies with larger cohorts are needed to confirm these findings and to evaluate additional factors influencing outcomes.